Decapeptide-12 137665-91-9

98% up by HPLC

Product categories

New Products

Product Details

Product Information

Product name	Decapeptide-12
CAS No.	137665-91-9
Sequence	H-Tyr-Arg-Ser-Arg-Lys-Tyr-Ser-Ser-Trp-Tyr-OH
Molecular Formula	C33H65N5O5
Molecular Weight	1395.55
Quality Standard	98% up by HPLC
Appearance	White lyophilized powder

COA of Decapeptide-12

TEST	SPECIFICATION	RESULTS
Appearance	White Powder	Complies
Odor	Characteristic	Complies
Tasted	Characteristic	Complies
Assay	99%	Complies
Sieve Analysis	100% pass 80 mesh	Complies
Loss on Drying	5% Max.	1.02%
Sulphated Ash	5% Max.	1.3%
Extract Solvent	Ethanol & Water	Complies
Heavy Metal	5ppm Max	Complies
As	2ppm Max	Complies
Residual Solvents	0.05% Max.	Negative
Microbiology
Total Plate Count	1000/g Max	Complies
Yeast & Mold	100/g Max	Complies
E.Coli	Negative	Complies
Salmonella	Negative	Complies
Conclusion	Conforms with the standards

Usage

Function of Decapeptide-12

Decapeptide-12 is a cosmetic raw material that inhibits the formation of melanin, diminishes pigmentation, reduces pigmentation, and even and brightens the skin tone. It was developed by researchers from the Department of Dermatology at Stanford University. It is currently the only one that has been proven to effectively inhibit the skin A novel peptide with tyrosinase activity.

Decapeptide-12 can inhibit the synthesis of tyrosinase, thereby effectively (40%) reducing the production of melanin. It can minimize chloasma, freckles, age spots, sunburn, uneven skin tone and light damage caused by over-pigmentation. And decapeptide-12 does not have the toxicity and side effects of other whitening ingredients such as hydroquinone, such as allergies, irritation and redness.

Application of Decapeptide-12

Decapeptide-12 is always used in skin linghtening creams,serums,gel,lotion.

Hot Tags : Decapeptide-12 Decapeptide Lumixyl cosmetic peptide Decapeptide cosmetic polypeptide supplier

Send A Message

Related Products

Liraglutide 204656-20-2

Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage 2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: · Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. · Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). · Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. · Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.